AbCellera Biologics Inc. (ABCL)
After hours:
| Previous close | 10.11 |
| Open | 9.98 |
| Bid | 10.45 x 1200 |
| Ask | 10.87 x 3000 |
| Day's range | 9.94 - 10.95 |
| 52-week range | 5.42 - 22.63 |
| Volume | |
| Avg. volume | 2,534,141 |
| Market cap | 2.999B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 16.54 |
| EPS (TTM) | 0.64 |
| Earnings date | 28 Mar 2022 - 01 Apr 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.13 |
- Business Wire
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
VANCOUVER, British Columbia, June 29, 2022--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022. Del
- Simply Wall St.
Insiders rewarded with a US$7.1m addition on top of their US$20m purchase as AbCellera Biologics Inc. (NASDAQ:ABCL) hits US$2.9b
Insiders who bought AbCellera Biologics Inc. ( NASDAQ:ABCL ) stock in the last 12 months were richly rewarded last...
- Zacks
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
